PART I Item 1. Bu siness. Overview We are a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, which we refer to collectively as our Candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-212 for the treatment of Friedreichs ataxia (FA), SGT-501 for the treatment of Catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy (TNNT2 DCM), ...
Q2 FY2026 — expected 2026-09-28
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-19 | 2025-12-31 | 0001193125-26-115928 | EDGAR | 115K words |
| 2025-03-06 | 2024-12-31 | 0000950170-25-034644 | EDGAR | — |
| 2024-03-13 | 2023-12-31 | 0000950170-24-030508 | EDGAR | — |
| 2023-03-23 | 2022-12-31 | 0000950170-23-009318 | EDGAR | — |
| 2022-03-14 | 2021-12-31 | 0001564590-22-009963 | EDGAR | — |
| 2021-03-15 | 2020-12-31 | 0001564590-21-013153 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001564590-20-010247 | EDGAR | — |
| 2019-03-13 | 2018-12-31 | 0001564590-19-007462 | EDGAR | — |
| 2018-03-29 | 2017-12-31 | 0001193125-18-100742 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-03 | 2025-09-30 | 0001193125-25-262818 | EDGAR | 70K words |
| 2025-08-12 | 2025-06-30 | 0000950170-25-107279 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0000950170-25-072560 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0000950170-24-122247 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096130 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0000950170-24-060034 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0000950170-23-061096 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0000950170-23-042371 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-020851 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024163 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016643 | EDGAR | — |
| 2022-04-27 | 2022-03-31 | 0001564590-22-015867 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-12 | 0001193125-26-102489 | EDGAR | 2K words |
| 2026-03-06 | 0001193125-26-096709 | EDGAR | — |
| 2025-11-03 | 0001193125-25-262795 | EDGAR | — |
| 2025-06-13 | 0000950170-25-086215 | EDGAR | — |
| 2025-05-15 | 0000950170-25-072792 | EDGAR | — |
| 2025-02-18 | 0001193125-25-028691 | EDGAR | — |
| 2025-02-18 | 0001193125-25-028146 | EDGAR | — |
| 2025-02-18 | 0001193125-25-028123 | EDGAR | — |
| 2024-06-11 | 0001193125-24-159143 | EDGAR | — |
| 2024-01-08 | 0001193125-24-003882 | EDGAR | — |
129 total filings indexed. 98 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001707502 |
| Ticker | SLDB |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.solidbio.com |
| Listed | 2018-01-25 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report